US 12,274,751 B2
Composition and method of the use of colchicine oral liquid
Indu Muni, North Reading, MA (US); and Naomi Vishnupad, Reading, MA (US)
Assigned to RxOMEG Therapeutics LLC, Woburn, MA (US)
Filed by RxOMEG Therapeutics LLC, Woburn, MA (US)
Filed on Dec. 9, 2019, as Appl. No. 16/707,093.
Application 15/818,905 is a division of application No. 15/358,621, filed on Nov. 22, 2016, granted, now 9,907,751.
Application 16/707,093 is a continuation of application No. 15/818,905, filed on Nov. 21, 2017, abandoned.
Claims priority of provisional application 62/306,232, filed on Mar. 10, 2016.
Prior Publication US 2020/0108147 A1, Apr. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/36 (2006.01); A61K 9/00 (2006.01); A61K 31/165 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01)
CPC A61K 47/36 (2013.01) [A61K 9/0095 (2013.01); A61K 31/165 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01)] 6 Claims
 
1. A method of treating gout, comprising orally administering a composition, comprising a liquid colchicine formulation to a human subject having gout in an effective amount to treat the gout, wherein the liquid colchicine formulation comprises colchicine in an amount of about 0.01-0.015% (w/v) and a pharmaceutically acceptable solvent system comprising water, one or more buffering agents comprising about 0.1-0.3% (w/v) citric acid in combination with about 0.8%-1.6% (w/v) dibasic sodium phosphate, about 2-8% (w/v) propylene glycol, about 0.2%-0.4% (w/v) of benzyl alcohol, optionally one or more sweeteners, optionally one or more flavoring agents, optionally one or more preservatives, and optionally one or more dyes, and wherein the liquid colchicine formulation has a stable pH.